The Importance of Clinical Grading of Heart Failure and Other Cardiac Toxicities During Chemotherapy: Updating the Common Terminology Criteria for Clinical Trial Reporting

Heart Failure Clinics

Volumn 7, Issue 3, 2011, Pages 373-384

  Hossain, Akm ^a   Chen, Alice ^b   Ivy, Percy ^b   Lenihan, Daniel J ^c   Kaltman, Jonathan ^d   Taddei Peters, Wendy ^d   Remick, Scot C ^e  

^a UNIVERSITY OF MISSOURI   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Cardiac side effects of chemotherapy; Cardiooncology; Common terminology criteria for adverse events

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CLOFARABINE; COMBRETASTATIN A4 PHOSPHATE; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GEMCITABINE; HYPERTENSIVE FACTOR; IDARUBICIN; IFOSFAMIDE; IMATINIB; LAPATINIB; N ACETYLCOLCHINOL PHOSPHATE; NILOTINIB; PACLITAXEL; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; VADIMEZAN; VORINOSTAT;

ACUTE CORONARY SYNDROME; ANGINA PECTORIS; ARTIFICIAL HEART PACEMAKER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVOR; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONTINUOUS INFUSION; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG SAFETY; ELECTROCARDIOGRAM; FOLLOW UP; HEART ARRHYTHMIA; HEART ASSIST DEVICE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART SURGERY; HEART TRANSPLANTATION; HEART VENTRICLE FAILURE; HUMAN; HYPERTENSION; MONOTHERAPY; PANCREAS CANCER; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; QT PROLONGATION; REVIEW; SINUS BRADYCARDIA; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION;

ANTINEOPLASTIC AGENTS; CARDIOTOXINS; CARDIOVASCULAR DISEASES; DRUG TOXICITY; EARLY DIAGNOSIS; HUMANS; NEOPLASMS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC;

EID: 79960210309     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.03.008     Document Type: Review

References (42)

1. Available at: Accessed April 16, 2011. http://www.SEER.Cancer.Gov.
2. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582.
3. Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000, 22:263-302.
4. Gharib M.I., Burnett A.K. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002, 4:235-242.
5. Van Heeckeren W.J., Bhakta S., Remick S.C., et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?. J Clin Oncol 2006, 24(10):1485-1488.
6. Sereno M., Brunello A., Chiappori A., et al. Cardiac toxicity: old and new issues in anti-cancer drugs. Clin Transl Oncol 2008, 10(1):35-46.
7. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009, 53(24):2231-2247.
8. Cardinale D. A new frontier: cardio-oncology. Cardiologia 1996, 41(9):887-891.
9. Saad A., Beta R., Abraham J., et al. Cardiovascular safety and toxicity profile of new molecular targeted anticancer agents 2008, 428-434. American Society of Clinical Oncology, Alexandria (VA).
10. Lipshultz S.E., Alvarez J.A., Scully R.E. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008, 94:525-533.
11. Grenier M.A., Lipshultz S.E. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998, 25:72-85.
12. Wouters K.A., Kremer L.C., Lipshultz S.E., et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005, 131:561-578.
13. Swain S.M., Whaley F.C., Gerber M.C., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997, 15:1318-1332.
14. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979, 91:710-717.
15. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003, 97:2869-2879.
16. Quezado Z.M., Wilson W.H., Cunnion R.E., et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993, 118:31-36.
17. Martin M., Pienkowski T., Mackey J., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313.
18. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.
19. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
20. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
21. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
22. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
23. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002, 20:1215-1221.
24. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118:84-95.
25. Schall R., Ring A. Statistical characterization of QT prolongation. J Biopharm Stat 2010, 20(3):543-562.
26. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
27. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
28. Perez E.A., Koehler M., Ewer M.S., et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008, 83:679-686.
29. Kerkela P., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.
30. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.
31. Soignet S.L., Frankel S.R., Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
32. Huang S.Y., Chang C.S., Tang J.L., et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol 1998, 103:1092-1095.
33. Ohnishi K., Yoshida H., Shigeno K., et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002, 16:617-622.
34. Kaur A., Yu S.S., Chiao T.B. Thalidomide-induced sinus bradycardia. Ann Pharmacother 2003, 37:1040-1043.
35. Morandi P., Ruffini P.A., Benvenuto G.M., et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant 2005, 35:323-334.
36. Rajkumar S.V. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 2005, 80:1549-1551.
37. Rodeghiero F., Elice F. Thalidomide and thrombosis. Pathophysiol Haemost Thromb 2003, 33(Suppl 1):15-18.
38. Available at: Accessed April 16, 2011. http://ctep.cancer.gov/branches/pio/reporting_guidelines.htm.
39. Available at: Accessed April 16, 2011. https://ctep.cancer.gov/protocoldevelopment.
40. Available at: Accessed April 16, 2011. https://cabig.nci.nih.gov.
41. Available at: Accessed April 16, 2011. https://cabig-kc.nci.nih.gov/Vocab/KC/index.php/CTCAE.
42. Available at: Accessed April 16, 2011. http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf.